TABLE 3.
Landmark trials for adjuvant chemo/chemoradiation therapy for locally advanced gastric cancer
| Trial name | Adjuvant | Experimental | Outcome | Control | Experimental | Hazard ratio (95% CI) | P value |
|---|---|---|---|---|---|---|---|
| START‐2 a , 54 | S‐1 alone | DS | 3‐year RFS | 50% | 66% | 0.632 (0.400‐0.998 b ) | <.001 |
| JCOG1104 53 | S‐1 for 1 year | S‐1 for 6 months | RFS (3‐year) | 93.1% | 89.8% | 1.84 (0.93‐3.63) | n/a |
| ARTIST‐2 57 | S‐1 alone |
SOX SOXRT |
DFS (3‐year) | 65% |
78% 73% |
0.617 (n/a) 0.686 (n/a) |
.0157 .0572 |
| CRITICS 58 | ECF/ECX/EOX | Additional RT 45Gy | OS | 43 months | 37 months | 1.01 (0.84‐1.22) | .90 |
Abbreviations: CI, confidence interval; DFS, disease‐free survival; DS, docetaxel + cisplatin; ECF, epirubicin + cisplatin+fluorouracil; ECX, epirubicine + cisplatin+capecitabine; EOX, epirubicine + oxaliplatin+capecitabine; n/a, not available; OS, overall survival; RFS, relapse‐free survival; RT, radiation therapy; SOX, S‐1 + oxaliplatin.
a
JACCRO‐GC 07.
b
99.99% confidence interval.